GHK-Cu is being considered for hair growth, but users report mixed results. Some use it alongside other treatments like 5AR inhibitors, making it hard to determine its effectiveness.
Using tretinoin with minoxidil may improve absorption but results vary; some users see improved follicle growth while others notice no significant difference. Applying tretinoin before minoxidil is suggested by some users.
The conversation is about a user expressing concerns over the safety of a new drug called Pyrilutamide (also known as KX-826) for hair loss. The user will only trust the drug if it's permitted by EU regulations and sold by a reputable company.
A user is considering a solution with 7% minoxidil, 0.25% finasteride, and 0.0125% tretinoin for hair loss, as suggested by their dermatologist. Other users share their experiences with similar treatments, noting mixed results and suggesting stronger alternatives like dutasteride.
Considering a hair transplant, using Pyrilutamide, the potential availability of CosmeRNA, and the significance of taking Minoxidil and Finasteride for long-term results.
A group buy for testing a compound targeting Twist1 protein as a potential hair loss treatment. Inhibiting Twist1, which keeps hair follicles in growth phase, may prevent hair loss with minimal side effects.
A 35-year-old transgender woman experienced hair regrowth with feminizing HRT, adding dutasteride and bicalutamide, and plans a hair transplant for further improvement. Estrogen also improved skin appearance, and the user advises against cisgender men using feminizing HRT for hair regrowth.
RepliCel has purchased Trichoscience, and they have a video about hair multiplication. The conversation also mentions treatments like Minoxidil, finasteride, and RU58841.
The conversation discusses hair loss treatments, specifically using Minoxidil, finasteride, and RU58841. It also mentions the importance of raising vitamin D3 levels.
The conversation discusses a topical formula for hair loss including Finasteride (0.025%), Minoxidil (0.5%), Tretinoin (0.01%), Caffeine (0.005%), Melatonin (0.003%), Tea Tree Oil (0.05%), Aloe (0.05%), Biotin (0.05%), and Fagron TrichoXidil (2.5%). The user considers removing Minoxidil and Tretinoin to test TrichoXidil's effectiveness.
The conversation is about hair loss treatments. The user considers using a foam with Saw palmetto, caffeine, and EGCG, but another user suggests just using finasteride.
The conversation discusses using 1% cetirizine, an antihistamine, as a potential treatment for androgenetic alopecia (hair loss). One user plans to try cetirizine instead of finasteride, while others are curious or skeptical about its effectiveness, discussing the role of inflammation in hair loss.
The conversation discusses a personal theory on the role of DHT in stress and reproduction, suggesting it converts testosterone for reproductive traits. The discussion includes skepticism and mentions individual differences in physiology and neurochemistry.
Mixing tretinoin with minoxidil for hair loss treatment. Some users prefer separate application or professional compounding due to potential solubility issues.
The user is excited about starting Clascoterone 5% for hair loss, a DHT blocker, and expects better results when combined with Minoxidil. The prescription costs $199 for 30 ml or $353 for 60 ml, and the user plans to cover the cost by driving for Uber.
The conversation discusses a personalized hair loss treatment plan based on DNA test results, recommending Minoxidil, Dutasteride, 17-alpha Estradiol, Cetirizine, and PRP sessions. The test identifies a high risk of hair loss due to DHT but a good response to Minoxidil, suggesting a tailored approach to treatment.
Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.
The conversation is about treatments for androgenetic alopecia, focusing on hyperresponders. Treatments include Minoxidil, finasteride, RU58841, leg training, and cold therapy.
Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. A user asks about alfatradiol's availability, public perception, and usage in Germany.
The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.
The conversation is about the availability of gt20029 for hair loss treatment, indicating that it will not be available for purchase soon. No specific treatments were discussed.
PP405 shows promise in activating dormant hair follicles and increasing hair counts but lacks detailed efficacy data compared to minoxidil and finasteride. Opinions are mixed, with some optimism and skepticism about its effectiveness.
A user has been using minoxidil without noticing improvements and is considering adding tretinoin gel to their regimen before trying RU58841. They seek advice on how to mix and apply tretinoin with minoxidil, including concentration and application frequency.
The conversation is about when the phase 3 results for pyrilutamide, a potential hair loss treatment, will be released. There was a letter about the study a month ago, but the actual results were not included.
A user is seeking a Minoxidil Response Test kit in the EU without bundled consultations. They mention alternatives like oral minoxidil and tretinoin but prefer the test alone.